Portland scientists at Oregon Health & Science University say they have figured out why pancreatic tumors so often brush off ...
Over the past 20 years, a class of anticancer drugs called CD40 agonist antibodies has shown great promise but also induced great disappointment. While such drugs have been effective at activating the ...
Morning Overview on MSN
One-shot vaccine injected into tumors shows promise for boosting survival
A single injection of a redesigned immune-stimulating antibody directly into a tumor was linked to shrinkage not only at the ...
Future studies may look at targeting the CD40 pathway as a potential therapeutic target ORLANDO, DECEMBER 7, 2025 - Researchers at The University of Texas MD Anderson Cancer Center have characterized ...
Treatment with the investigational CD40 ligand inhibitor frexalimab significantly reduced new MRI lesions in relapsing multiple sclerosis (MS) by week 24, according to data presented at the joint ...
CHICAGO -- The investigational CD40 agonist mitazalimab and modified FOLFIRINOX demonstrated encouraging activity in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, ...
A plasma-based proteomic platform for predicting clinical benefit from immune checkpoint inhibitors in multiple cancers. Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for ...
Veronica Paulus is a former STAT intern supported by the Harvard University Institute of Politics. Marissa Russo is a former STAT intern supported by the AAAS Mass Media Science & Engineering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results